Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of BBT-401-1S in Ulcerative Colitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03800420
Recruitment Status : Recruiting
First Posted : January 11, 2019
Last Update Posted : October 24, 2019
Sponsor:
Collaborator:
KCRN Research, LLC
Information provided by (Responsible Party):
Bridge Biotherapeutics, Inc.

Brief Summary:

This is randomized, placebo-controlled, dose-escalation, multicenter, Phase 2 study to evaluate the efficacy and safety of BBT-401-1S in patients with active ulcerative colitis.

This study consists of three cohorts with 16-week treatment period per cohort that will be conducted sequentially.


Condition or disease Intervention/treatment Phase
Ulcerative Colitis Drug: Active group Drug: Placebo group Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

'Dose level 1' will be conducted first. 'Dose level 2' and 'Dose level 3' will be started sequentially.

Subject will be randomized to active or placebo group in each dose level cohort.

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of BBT-401-1S in Patients With Active Ulcerative Colitis
Actual Study Start Date : April 22, 2019
Estimated Primary Completion Date : August 1, 2020
Estimated Study Completion Date : December 15, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: BBT-401-1S, dose level 1
BBT-401-1S or placebo, Oral capsule, QD
Drug: Active group
BBT-401-1S 12 weeks + Placebo 4 weeks

Drug: Placebo group
Placebo 8 weeks + BBT-401-1S 8 weeks

Experimental: BBT-401-1S, dose level 2
BBT-401-1S or placebo, Oral capsule, QD
Drug: Active group
BBT-401-1S 12 weeks + Placebo 4 weeks

Drug: Placebo group
Placebo 8 weeks + BBT-401-1S 8 weeks

Experimental: BBT-401-1S, dose level 3
BBT-401-1S or placebo, Oral capsule, QD
Drug: Active group
BBT-401-1S 12 weeks + Placebo 4 weeks

Drug: Placebo group
Placebo 8 weeks + BBT-401-1S 8 weeks




Primary Outcome Measures :
  1. Change from Baseline in Total Mayo Score [ Time Frame: Week 8 ]

    Total Mayo Score (0-12): Sum of stool frequency (0-3), rectal bleeding (0-3), endoscopic findings (0-3), physician's global assessment (0-3).

    Lower values represent a better outcome.



Secondary Outcome Measures :
  1. Change from Baseline in Partial Mayo Score [ Time Frame: Week 8 ]

    Partial Mayo Score (0-9): Sum of stool frequency (0-3), rectal bleeding (0-3), physician's global assessment (0-3).

    Lower values represent a better outcome.


  2. Change from Baseline in Histologic Assessment of Endoscopic Biopsy [ Time Frame: Week 8 ]
    Biopsy samples will be assessed in Geboes score (0-6). Lower values represent a better outcome.

  3. Change from Baseline in Ulcerative Colitis Endoscopic Index of Severity (0-8) [ Time Frame: Week 8 ]
    Lower values represent a better outcome.

  4. Number and Severity of TEAEs [ Time Frame: up to 8 weeks after the last dose ]
    Assess the efficacy and safety of multiple oral doses of BBT-401- 1S in patients with active UC

  5. Plasma Concentration of BBT- 401-1S [ Time Frame: Day 1, Week 4, Week 8 ]
    Assess the plasma concentration of multiple oral doses of BBT-401-1S in patients with active UC

  6. Change from Baseline in Concentration of Serum CRP [ Time Frame: Week 8 ]
    Evaluate the effects of BBT-401-1S on biomarkers

  7. Change from Baseline in Concentration of Fecal Calprotectin [ Time Frame: Week 8 ]
    Evaluate the effects of BBT-401-1S on biomarkers

  8. Change from Baseline in Concentration of Fecal Lactoferrin [ Time Frame: Week 8 ]
    Evaluate the effects of BBT-401-1S on biomarkers



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provision of signed and dated informed consent form (ICF)
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged >=18 years
  • Diagnosed with active UC for at least 3 months prior to screening
  • Total Mayo score >=5 and Endoscopic sub-score >=1
  • Stable dosing regimens of oral drugs (if currently administered) as follows: 5-ASA or sulfasalazine at a stable dose for at least 4 weeks, purine analogues (azathioprine, mercaptopurine, thiopurines) or methotrexate at a stable dose for at least 12 weeks, and low-dose oral corticosteroid (up to 20 mg prednisone/day or equivalent) for at least 4 weeks prior to the first dose of study treatment. Doses of oral drugs must remain stable until the end of study treatment (with possible exception for tapering steroid dose after 8 weeks)
  • For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 3 months after the last dose
  • For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner during study participation and for an additional 3 months after the last dose

Exclusion Criteria:

  • Use of anti-TNF-a biologics or any other biologics for treatment of UC within 60 days prior to randomization.
  • Any rectal therapy for treatment of UC or intravenous corticosteroids within 2 weeks prior to randomization.
  • Presence of Crohn's disease, indeterminate colitis, ischemic colitis, fulminant colitis, ulcerative proctitis, or toxic mega-colon
  • Previous extensive colonic resection (subtotal or total colectomy)
  • Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine
  • Evidence of or treatment for Clostridium difficile infection or other pathogenic bowel infection within 60 days or for another intestinal pathogen within 30 days prior to randomization
  • Active infection with the HIV or Hepatitis B or C viruses
  • Clinically significant active extra-intestinal infection (e.g., pneumonia, pyelonephritis)
  • Clinically significant abnormal vital signs, physical examination or 12-lead electrocardiogram (ECG) at screening or baseline
  • Clinically significant abnormal results of liver function tests (ALT/AST, bilirubin and alkaline phosphatase) > 2X the upper limit of normal (ULN) at screening
  • Other clinically significant abnormal laboratory results at screening in the investigator's opinion
  • History of any clinically significant medical condition that, in the investigator's opinion, would preclude participation in the study
  • Pregnancy or lactation
  • Treatment with another investigational drug or other intervention within 30 days prior to screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03800420


Contacts
Layout table for location contacts
Contact: Hugh Lee 240-421-3190 hughlee@kcrnresearch.com

Locations
Layout table for location information
United States, California
Site 03 Recruiting
Sacramento, California, United States, 95821
Site 01 Recruiting
Ventura, California, United States, 93003
United States, Florida
Site 11 Recruiting
Boca Raton, Florida, United States, 33487
Site 12 Recruiting
Pembroke Pines, Florida, United States, 33029
United States, Maryland
Site 04 Recruiting
Rockville, Maryland, United States, 20850
United States, Michigan
Site 10 Not yet recruiting
Ann Arbor, Michigan, United States, 48109
United States, North Carolina
Site 02 Recruiting
Monroe, North Carolina, United States, 28112
United States, Tennessee
Site 08 Recruiting
Chattanooga, Tennessee, United States, 37421
United States, Texas
Site 05 Recruiting
Austin, Texas, United States, 78705
Site 13 Recruiting
McAllen, Texas, United States, 78503
United States, Washington
Site 09 Not yet recruiting
Seattle, Washington, United States, 98195
Sponsors and Collaborators
Bridge Biotherapeutics, Inc.
KCRN Research, LLC
Investigators
Layout table for investigator information
Study Director: Jeong-Hyun Ryou, M.D., Ph.D. Bridge Biotherapeutics, Inc.

Layout table for additonal information
Responsible Party: Bridge Biotherapeutics, Inc.
ClinicalTrials.gov Identifier: NCT03800420     History of Changes
Other Study ID Numbers: BBT401-UC-US02
First Posted: January 11, 2019    Key Record Dates
Last Update Posted: October 24, 2019
Last Verified: October 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bridge Biotherapeutics, Inc.:
Pellino-1
Additional relevant MeSH terms:
Layout table for MeSH terms
Colitis
Colitis, Ulcerative
Ulcer
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases